Compounded GLP-1 Medications: What You Need to Know

What Are Compounded GLP-1 Medications?

Compounded GLP-1 medications are custom-prepared versions of semaglutide or tirzepatide created by licensed pharmacies to meet individual patient needs. Unlike brand-name medications (Ozempic, Wegovy, Mounjaro), compounded drugs are not FDA-approved products. However, they are legal and regulated when prepared under specific conditions. If you're eligible for brand-name GLP-1s, check our eligibility guide to understand your options.

The FDA permits compounding in two main ways:

• 503A Compounding: Individual pharmacies prepare medications for specific patients based on a doctor's prescription. These are customized, smaller-batch preparations.
• 503B Compounding: Outsourcing facilities manufacture larger quantities for multiple patients without a specific prescription on file. These are more standardized than 503A but still not FDA-approved.

How Compounding Works

Compounding became increasingly common for GLP-1 medications due to significant brand-name shortages. Here's what you need to understand:

The FDA Shortage List

The FDA maintains a Drug Shortages list that tracks which medications are in short supply. When a medication appears on this list, the FDA permits licensed pharmacies to compound alternatives without a pre-existing prescription.

Regulatory Timeline

Semaglutide and tirzepatide shortages began in 2023 due to overwhelming demand for weight-loss use. Compounding became a legal workaround to meet patient demand when brand-name options were unavailable or extremely expensive. Here's what changed in 2025-2026:

• February 21, 2025: FDA ended the semaglutide shortage.
• December 2024: Tirzepatide shortage was declared resolved.
• 503A pharmacies: May still compound if prescriber documents "patient-specific change" — cannot make "essentially copies" of available products.
• 503B facilities: Were required to stop compounding GLP-1s by May 22, 2025, though litigation (Outsourcing Facilities Association lawsuit in Northern District of Texas) created ongoing regulatory uncertainty.
• March 3, 2026: FDA issued 30 warning letters to telehealth companies offering compounded GLP-1s.
• February 7, 2026: FDA announced "decisive steps" to restrict compounded GLP-1s and stabilize the supply of brand-name products.

This is an important context: compounded GLP-1s were created during a genuine supply crisis. Your prescription will still be valid if your doctor prescribes a compounded formulation, but you should understand that these are not the same as brand-name products in terms of regulatory oversight or supply guarantees. The regulatory landscape is tightening significantly.

Read FDA's full clarification on compounding policies and supply stabilization →

The FDA Shortage Situation: What Changed

In late 2023 and early 2024, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) shortages were critical. Manufacturing couldn't keep pace with demand. This is what enabled compounding to flourish.

By April 2026, the regulatory environment has shifted dramatically:

• Shortages officially ended: FDA ended semaglutide shortage Feb 21, 2025; tirzepatide resolved Dec 2024.
• Stricter 503A rules: Compounding only allowed if prescriber documents a "patient-specific change" — pharmacies cannot make copies of available brand-name products.
• 503B shuttered: Outsourcing facilities were required to stop by May 22, 2025 (with ongoing litigation uncertainty).
• FDA enforcement: 30 warning letters to telehealth companies (March 2026); FDA "decisive steps" announced (Feb 2026).
• Insurance expansion: Brand-name coverage improved; Wegovy oral pill FDA-approved Jan 2026; cost gap narrowing.

The upshot: compounded GLP-1s remain technically available, but the regulatory justification has largely disappeared. Availability is declining, and telehealth platforms are rapidly shifting to FDA-approved alternatives. If you're considering compounded GLP-1s, understand this market is in active regulatory contraction.

Compounded vs Brand-Name: Key Differences

Understanding the distinctions helps you make an informed choice:

Factor	Brand-Name (Wegovy, Ozempic)	Compounded
FDA Approval	Fully FDA-approved	Not FDA-approved; prepared under FDA oversight during shortages
Cost	$900–1,300/month (often covered by insurance)	$69–199/month (rarely covered by insurance)
Insurance Coverage	Possible with prior authorization	Almost never covered; out-of-pocket only
Supply Consistency	Consistent manufacturing standards	Varies by pharmacy; less rigorous quality control
Dosing Flexibility	Standard doses only	Custom doses available (e.g., 1.2 mg, 2.0 mg, 2.5 mg)
Active Ingredient Source	Novo Nordisk (semaglutide) or Eli Lilly (tirzepatide)	Bulk powder from various suppliers; quality varies
Shelf Life / Stability	Tested and guaranteed	Varies; typically 30–60 days in some formulations

Cost Comparison

Cost is often the primary driver for choosing compounded GLP-1s. However, the price gap has narrowed significantly in 2026 as brand-name options have become cheaper. Here's what patients typically pay (as of April 2026). For a full breakdown of insurance coverage, see our guide to GLP-1 insurance and out-of-pocket costs:

• Compounded Semaglutide: $199–599 per month (prices have risen due to regulatory pressure and reduced availability).
• Brand-Name Wegovy (oral pill): $199/month for first two fills; $349/month for higher doses (FDA-approved January 2026).
• Brand-Name Wegovy (injection): ~$1,300 per month (uninsured); covered by some insurance plans.
• Brand-Name Ozempic: ~$900 per month (uninsured); often covered for diabetes but not weight loss.
• Brand-Name Zepbound (tirzepatide): $299–449 per month via LillyDirect (reduced from $349–499).
• Brand-Name Mounjaro: ~$1,350 per month (uninsured); emerging insurance coverage.

Key shift: The cost advantage of compounded options has eroded substantially. Compounded prices have risen due to regulatory uncertainty, while brand-name options (especially Wegovy oral pill and LillyDirect pricing) have become more affordable. For many patients, brand-name alternatives now offer comparable pricing with regulatory certainty.

Programs Offering Compounded GLP-1s

Several telehealth and direct-to-patient programs now offer compounded semaglutide and tirzepatide. Here are the main players:

Safety Considerations

Choosing compounded GLP-1s carries real health considerations. Before you decide, make sure you understand the potential side effects of any GLP-1 medication. Here's what you should verify:

Red Flags to Avoid

Be cautious of:

• No prescription required: Legitimate compounding always requires a doctor's prescription.
• Prices that seem too good to be true: Under $50/month is a warning sign of poor quality or unlicensed operation.
• Overseas shipping: Compounded medications shipped from international sources bypass FDA oversight entirely.
• No pharmacist availability: Reputable services have licensed pharmacists available for questions.
• Claims of "FDA-approved compounding": Compounding itself is never FDA-approved; only the active ingredient can be.

What the FDA Has Found

The FDA has documented significant safety concerns with compounded GLP-1 medications. As of April 2026, here's what the data shows:

These data underpin the FDA's shift toward stricter enforcement. The agency issued 30 warning letters in March 2026 and announced decisive regulatory steps in February 2026 to reduce compounded GLP-1 market share.

Read the FDA's full safety concerns document →

Medicare GLP-1 Bridge Program (Starting July 2026)

Starting July 1, 2026, Medicare Part D enrollees will gain temporary access to select GLP-1s for obesity through the Medicare GLP-1 Bridge program. Out-of-pocket costs will be capped at approximately $50 per month through December 2026. This represents a major expansion of affordable access to brand-name GLP-1s for seniors and may reduce the appeal of compounded alternatives.

Who Should Consider Compounded GLP-1s?

Good Candidates

• Patients without insurance or with plans that don't cover weight-loss GLP-1s.
• Those who need non-standard dosing (e.g., you prefer 2.0 mg instead of the standard 1.7 mg).
• Individuals who've experienced shortages of brand-name medications.
• Cost-sensitive patients for whom the price difference ($900 vs $99/month) is life-changing.
• People with specific allergies or sensitivities to brand-name formulation ingredients.

Poor Candidates

• Patients with comprehensive insurance that covers brand-name GLP-1s. Use your coverage.
• Those uncomfortable with non-FDA-approved medication status. That's a valid concern.
• Anyone who cannot access reliable pharmacist support or ongoing care coordination.
• Patients with complex medical histories who benefit from the strict oversight brand-name medications receive.

Frequently Asked Questions

Sources & FDA Resources

All information on this page is based on official FDA guidance and published studies. For the most current information, refer to these authoritative sources:

• FDA Drug Shortages Official List
• FDA: Clarification on Compounding Policies and GLP-1 Supply Stabilization
• FDA: Safety Concerns with Unapproved GLP-1 Drugs for Weight Loss
• CNBC: Novo Nordisk Sues Hims & Hers Over Compounded Obesity Drugs
• FDA News & Press Announcements (for warning letters and enforcement actions)